The clinical significance and oncogenic function of LRRFIP1 in pancreatic cancer

被引:3
作者
Li, Jinping [1 ]
Tuo, Dayun [1 ,2 ]
Guo, Gunan [1 ,3 ]
Gao, Yan [1 ]
Gan, Jinfeng [4 ,5 ]
机构
[1] Guilin Med Univ, Sch Preclin Med, Dept Histol & Embryol, Guilin 541199, Guangxi, Peoples R China
[2] Liuzhou Peoples Hosp, Dept Pathol, Liuzhou 545006, Guangxi, Peoples R China
[3] Zhaoqing Med Coll, Sch Stomatol, Zhaoqing 526020, Guangdong, Peoples R China
[4] Guilin Med Univ, Guangxi Key Lab Tumor Immunol & Microenvironm Regu, Guilin 541199, Guangxi, Peoples R China
[5] Guilin Med Univ, Affiliated Hosp 2, Dept Gastroenterol, Guilin 541199, Guangxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Pancreatic cancer; Prognosis; LRRFIP1; AKT; GSK-3; beta; beta-catenin; GROWTH; CELLS; GCF2/LRRFIP1; SENSITIVITY; INHIBITION; EXPRESSION; GCF2; RHOA;
D O I
10.1007/s12672-024-00977-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Pancreatic cancer is a lethal malignancy with a grim prognosis. Previous studies have proven that Leucine Rich Repeat of Flightless-1 Interacting Protein 1 (LRRFIP1) plays a pivotal role in cell biological processes, while its clinical significance and function in pancreatic cancer remain to be elucidated. Hence, we aimed to explore the roles and mechanisms of LRRFIP1 in pancreatic cancer. Methods The expression of LRRFIP1 in pancreatic cancer tissues and its clinical significance for pancreatic cancer were analyzed by immunohistochemistry assay and bioinformatic analysis. The influences of LRRFIP1 on the proliferation and migration of pancreatic cancer cells were assessed in vitro. The underlying mechanisms of LRRFIP1 in pancreatic cancer progression were explored using gene set enrichment analysis (GSEA) and molecular experiments. Results The results showed that LRRFIP1 expression was significantly upregulated in pancreatic cancer tissues compared to the normal tissues, and such upregulation was associated with poor prognosis of patients with pancreatic cancer. GSEA revealed that LRRFIP1 upregulation was significantly associated with various cancer-associated signaling pathways, including PI3K/AKT signaling pathway and Wnt pathway. Furthermore, LRRFIP1 was found to be associated with the infiltration of various immune cells. Functionally, LRRFIP1 silencing suppressed cell proliferation somewhat and inhibited migration substantially. Further molecular experiments indicated that LRRFIP1 silencing inactivated the AKT/GSK-3 beta/beta-catenin signaling axis. Conclusion Taken together, LRRFIP1 is associated with tumorigenesis, immune cell infiltration, and prognosis in pancreatic cancer, which suggests that LRRFIP1 may be a potential biomarker and therapeutic target for pancreatic cancer.
引用
收藏
页数:15
相关论文
共 32 条
[21]   GC-binding factor 2 interacts with Dishevelled and regulates Wnt signaling pathways in human carcinoma cell lines [J].
Ohtsuka, Hideo ;
Oikawa, Masaya ;
Ariake, Kyohei ;
Rikiyama, Toshiki ;
Motoi, Fuyuhiko ;
Katayose, Yu ;
Unno, Michiaki ;
Johnson, Alfred C. .
INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (07) :1599-1610
[22]   FKBP51 Affects Cancer Cell Response to Chemotherapy by Negatively Regulating Akt [J].
Pei, Huadong ;
Li, Liang ;
Fridley, Brooke L. ;
Jenkins, Gregory D. ;
Kalari, Krishna R. ;
Lingle, Wilma ;
Petersen, Gloria ;
Lou, Zhenkun ;
Wang, Liewei .
CANCER CELL, 2009, 16 (03) :259-266
[23]   GCF2: expression and molecular analysis of repression [J].
Rikiyama, T ;
Curtis, J ;
Oikawa, M ;
Zimonjic, DB ;
Popescu, N ;
Murphy, BA ;
Wilson, MA ;
Johnson, AC .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2003, 1629 (1-3) :15-25
[24]   The Transcription Factor GCF2 Is an Upstream Repressor of the Small GTPAse RhoA, Regulating Membrane Protein Trafficking, Sensitivity to Doxorubicin, and Resistance to Cisplatin [J].
Shen, Ding-Wu ;
Pouliot, Lynn M. ;
Gillet, Jean-Pierre ;
Ma, Wenting ;
Johnson, Alfred C. ;
Hall, Matthew D. ;
Gottesman, Michael M. .
MOLECULAR PHARMACEUTICS, 2012, 9 (06) :1822-1833
[25]   Cancer statistics, 2020 [J].
Siegel, Rebecca L. ;
Miller, Kimberly D. ;
Jemal, Ahmedin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2020, 70 (01) :7-30
[26]   AKT as a Therapeutic Target for Cancer [J].
Song, Mengqiu ;
Bode, Ann M. ;
Dong, Zigang ;
Lee, Mee-Hyun .
CANCER RESEARCH, 2019, 79 (06) :1019-1031
[27]   Multidisciplinary Roles of LRRFIP1/GCF2 in Human Biological Systems and Diseases [J].
Takimoto, Masato .
CELLS, 2019, 8 (02)
[28]   Toil enables reproducible, open source, big biomedical data analyses [J].
Vivian, John ;
Rao, Arjun Arkal ;
Nothaft, Frank Austin ;
Ketchum, Christopher ;
Armstrong, Joel ;
Novak, Adam ;
Pfeil, Jacob ;
Narkizian, Jake ;
Deran, Alden D. ;
Musselman-Brown, Audrey ;
Schmidt, Hannes ;
Amstutz, Peter ;
Craft, Brian ;
Goldman, Mary ;
Rosenbloom, Kate ;
Cline, Melissa ;
O'Connor, Brian ;
Hanna, Megan ;
Birger, Chet ;
Kent, W. James ;
Patterson, David A. ;
Joseph, Anthony D. ;
Zhu, Jingchun ;
Zaranek, Sasha ;
Getz, Gad ;
Haussler, David ;
Paten, Benedict .
NATURE BIOTECHNOLOGY, 2017, 35 (04) :314-316
[29]   Immune micro-environment analysis and establishment of response prediction model for PD-1 blockade immunotherapy in glioblastoma based on transcriptome deconvolution [J].
Wong, David ;
Yin, Yanhui .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (13) :11689-11703
[30]   Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells [J].
Yan, Wei ;
Wu, Xiwei ;
Zhou, Weiying ;
Fong, Miranda Y. ;
Cao, Minghui ;
Liu, Juan ;
Liu, Xiaojing ;
Chen, Chih-Hong ;
Fadare, Oluwole ;
Pizzo, Donald P. ;
Wu, Jiawen ;
Liu, Liang ;
Liu, Xuxiang ;
Chin, Andrew R. ;
Ren, Xiubao ;
Chen, Yuan ;
Locasale, Jason W. ;
Wang, Shizhen Emily .
NATURE CELL BIOLOGY, 2018, 20 (05) :597-+